Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
0.3656
-0.0095 (-2.53%)
At close: Jan 30, 2026, 4:00 PM EST
0.3770
+0.0114 (3.12%)
After-hours: Jan 30, 2026, 7:36 PM EST
Intensity Therapeutics Employees
As of December 31, 2024, Intensity Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,676,571
Market Cap
21.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 7 | 0 | - | 5 | 2 |
| Dec 31, 2023 | 7 | 3 | 75.00% | 5 | 2 |
| Mar 31, 2023 | 4 | -2 | -33.33% | 3 | 1 |
| Jun 30, 2022 | 4 | - | - | 4 | 0 |
| Mar 31, 2022 | 6 | - | - | 5 | 1 |
| Dec 31, 2021 | 6 | - | - | 5 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| CASI Pharmaceuticals | 233 |
| IO Biotech | 78 |
| Vistagen Therapeutics | 59 |
| CollPlant Biotechnologies | 57 |
| FibroBiologics | 13 |
| Genenta Science | 13 |
| Neuphoria Therapeutics | 8 |
| NanoViricides | 7 |
INTS News
- 18 days ago - Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities - PRNewsWire
- 7 weeks ago - Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium - PRNewsWire
- 2 months ago - Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - PRNewsWire
- 2 months ago - Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium - PRNewsWire
- 3 months ago - Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript - Seeking Alpha
- 3 months ago - Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock - PRNewsWire
- 3 months ago - Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal - PRNewsWire